AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...
The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.
AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...
AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, ...
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
Recarbrio – which based on established antibiotic combination imipenem/cilastatin with Merck’s new beta-lactamase inhibitor relebactam – has been cleared by the FDA for adults with ...
Together, they’re being studied as a potential treatment option for serious bacterial infections caused by antibiotic-resistant gram-negative bacteria, including Extended Spectrum Beta-lactamase ...
Hosted on MSN11mon
Orchid Pharma gets USFDA nod, to market its new drug in US soonThe company has received approval from the United States Food and Drug Administration (USFDA) for its invention Enmetaobactam, a Beta Lactamase Inhibitor. The company shares went up to Rs 1,217.20 ...
7d
AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback